Synthetic Peptides from a Hypothetical Receptor Binding Site: A Possible Approach to a Rhinovirus Vaccine?

  • Gudrun Werner
  • Joseph W. McCray
Conference paper

Abstract

Rhinoviruses are well established as the major causative agent of the common cold (Couch, 1984; Gwaltney, 1982). Since there are many methodological difficulties with diagnosis, estimates for the proportion of rhinoviruses among other virus families causing colds vary between 10 and more than 50% (Phillpotts and Tyrell, 1985). Although usually harmless in healthy children and adults, rhinovirus colds can induce severe complications in patients with chronic respiratory states like asthma or chronic bronchitis (Gregg, 1983). Rhinovirus has also been isolated from immunosuppressed infants with lower respiratory tract infections normally not caused by these viruses (Krilov et al. 1986). The economic burden of the common cold is enormous. According to a national health survey the common cold accounts for about 20% of all disabling conditions leading to roughly 30 million lost days of work per year in the United States alone (Couch, 1984). In contrast to the relative significance of the medical problem scientific efforts towards methods for control have been limited. There has been much optimism about antiviral drugs for prophylactic or therapeutic treatment of the disease. However, of the synthetic antirhinovirus compounds found to be active in vitro none proved effective in experimental or naturally occurring rhinovirus infections (Al-Nakib and Tyrell, 1987).

Keywords

Synthetic Peptide Human Rhinovirus Human Respiratory Syncytial Virus Intranasal Immunization Antipeptide Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abraham G, Colonno RJ (1984) Many rhinovirus serotypes share the same cellular receptor. J Virol 51: 340–345.PubMedGoogle Scholar
  2. Allen PM (1987)Antigen processing at the molecular level.Immunology Today 8:270–273.Google Scholar
  3. Al-Nakib W, Tyrell DAJ (1987) A ‘new’ generation of more potent synthetic anti-rhinovirus compounds: comparison of their MICs and their synergistic interactions. Antiviral Res 8: 179–188.PubMedCrossRefGoogle Scholar
  4. Anderer FA (1963) Preparation and properties of an artificial antigen immunologically related to tobacco mosaic virus. Biochim Biophys Acta 71: 246–248.PubMedCrossRefGoogle Scholar
  5. Arnon R (1986) Peptides as immunogens: prospects for synthetic vaccines. Current Topics Microbiol Immunol 130: 1–12.CrossRefGoogle Scholar
  6. Arnon R, Maron E, Sela M, Anfinsen CB (1971) Antibodies reactive with native lysozyme elicited by a completely synthetic antigen. Proc Natl Acad Sci USA 68: 1450–1455.PubMedCrossRefGoogle Scholar
  7. Ashwell DJ, Schwartz RH (1986) T-cell recognition of antigen and the Ia molecules as a ternary complex. Nature 320: 176–179.PubMedCrossRefGoogle Scholar
  8. Audibert F (1986) Carriers and adjuvants for the development of synthetic vaccines. In 1st Forum in Virology.Paris: Ann Inst. Pasteur/Virol. 137E:pp. 514–517.Google Scholar
  9. Audibert F, Jolivet M, Chedid L, Arnon R, Sela M (1982) Successful immunization with a totally synthetic diphtheria vaccine.Proc Natl Acad Sci USA 79: 5042–5046.CrossRefGoogle Scholar
  10. Beem M (1969) Rhinovirus infections in nursery school children (abstract). J Pediatr 74: 818–820.PubMedCrossRefGoogle Scholar
  11. Bittle JL, Houghten RA, Alexander H, Shinnik TM, Sutcliffe JG, Lerner RA, Rowlands DJ, Brown F (1982) Protection against foot-and-mouth-disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298: 30–33.PubMedCrossRefGoogle Scholar
  12. Buscho RF, Perkins JC, Knopf HLS, Kapikian AZ, Chanock RM (1972) Further characterization of the local respiratory tract antibody response induced by intranasal instillation of inactivated rhinovirus 13 vaccine. J Immunol 108: 169–177.PubMedGoogle Scholar
  13. Callahan PL, Mizutani S, Colonno RJ (1985) Molecular cloning and complete sequence determination of the RNA genome of human rhinovirus type 14. Proc Natl Acad Sci USA 82: 732–736.PubMedCrossRefGoogle Scholar
  14. Carrol AR, Rowlands DJ, Clarke BE (1984) The complete nucleotide sequence of the RNA coding for the primary translation product of foot and mouth disease virus. Nucl Acids Res 12: 2461–2472.CrossRefGoogle Scholar
  15. Chang CH, Short MT, Westholen FA, Stevens FJ, Wang BC, Furey Jr W, Solanai A, Schiffer M (1985) Novel arrangement of immunoglobulin variable domains: X-ray crystallographic analysis of the R-chain dimer Bence-Jones protein loc. Biochemistry 24: 4890–4897.Google Scholar
  16. Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, Kennedy RC (1986) Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 5: 3065–3071.PubMedGoogle Scholar
  17. Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP, LeFrancier PL (1982) Biological activity of a new synthetic muramyl peptide devoid of pyrogenicity. Infect Immun 35: 417–424.PubMedGoogle Scholar
  18. Cheung A, Leban J, Shaw AR, Merkli B, Stocker J, Chizzolini C, Sander C, Perrin LH (1986) Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc Natl Acad Sci USA 83: 8328–8332.PubMedCrossRefGoogle Scholar
  19. Chow M, Yabrov R. Bittle J, Bogle J, Baltimore D (1985). Synthetic peptides from four separate regions of the poliovirus type 1 capsid protein VP1 induce neutralizing antibodies. Proc Natl Acad Sci USA 82: 910–914.Google Scholar
  20. Cohen M (1971) The take-home lesson. Ann N.Y. Acad Sci 190: 529–584.CrossRefGoogle Scholar
  21. Collins PL, Huang YT, Wertz GW (1984) Nucleotide sequence of the gene encoding the fusion ( F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci USA 81: 7683–7687.Google Scholar
  22. Colonno RJ, Callahan PL, Long WJ (1986) Isolation of a monoclonal anti-body that blocks attachment of the major group of human rhinoviruses.J Virol 57: 7–12.Google Scholar
  23. Cooney MK, Fox JP, Kenney GE (1982) Antigenic groupings of 90 rhinovirus serotypes. Infect Immun 37: 642–647.PubMedGoogle Scholar
  24. Couch RB (1984) The common cold: control? J Infect Dis 150: 167–173.PubMedCrossRefGoogle Scholar
  25. Dale JB, Beachey EH (1982) Protective antigenic determinant of strepto-coccal M protein shared with sarcolemma membrane protein of human heart. J Exp Med 156: 1165–1176.PubMedCrossRefGoogle Scholar
  26. Delisi C, Berzofsky J (1985) T-cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci USA 82: 7048–7052.PubMedCrossRefGoogle Scholar
  27. DiMarchi R, Brooke G, Gale C, Crackwell V, Doel T, Mowat N (1986) Protection of cattle against foot-and-mouth disease by a synthetic peptide.Science 232: 639–641.Google Scholar
  28. Dimmock NJ (1987) Multiple mechanisms of neutralization of animal viruses. Trends Biochem Sci 12: 70–75.CrossRefGoogle Scholar
  29. Dreesman GR, Sanchez Y, Ionescu-Matin I, Sparrow JT, Six HR, Peterson DL, Hollinger FB, Melnick JL (1982) Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature 295: 158–160.PubMedCrossRefGoogle Scholar
  30. Duechler M, Skern T, Sommergruber W, Neubauer C, Grundler P, Fogy I, Blass D, Kuechler E (1987) Evolutionary relationships within the human rhinovirus genes: Comparison of serotypes 89,2 and 14. Proc Natl Acad Sci USA 84: 2605–2609.PubMedCrossRefGoogle Scholar
  31. Emini EA, Jameson BA, Wimmer E (1983a) Priming for and induction of anti-polio-virus neutralizing antibodies by synthetic peptides. Nature 304: 699–703.PubMedCrossRefGoogle Scholar
  32. Emini EA, Show YK, Lewis AJ, Crainic R, Wimmer E (1983b) Functional basis of poliovirus neutralization determined with monospecific neutralizing antibodies. J Virol 46: 466–474.PubMedGoogle Scholar
  33. Fox JP (1976) Reviews and commentary-is a rhinovirus vaccine possible? Am J Epidemiol 103: 345–354.PubMedGoogle Scholar
  34. Francis MJ, Fry CM, Rowlands DJ, Brown F, Bittle JL, Houghten RA,Lerner RA (1985) Immunological priming with synthetic peptides of foot-and-mouth disease virus. J Gen Virol 66: 2347–2354.Google Scholar
  35. Francis MJ, Hastings GZ, Syred AD, McGinn B, Brown F, Rowlands DJ (1987a) Non-responsiveness to a foot-and-mouth disease virus peptide overcome by addition of foreign helper T-cell determinants. Nature 300: 168170.Google Scholar
  36. Francis MJ, Hastings GZ, Sangar DV, Clark RP, Syred A, CIarke BE, Rowlands DJ, Brown F (1987b) A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. J Gen Virol 68: 2687–2691.PubMedCrossRefGoogle Scholar
  37. Gerin JL, Alexander H, Shih JWK, Purcell RH, Dapolito G, Engle R, Green N, Sutcliffe JG, Shinnick TM, Lerner RA (1983) Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. Proc Natl Acad Sci USA 80: 2365–2369.PubMedCrossRefGoogle Scholar
  38. Good MF, Maloy WL, Lunde MN, Margalit H, Cornette JL, Smith GL, Moss B, Miller LH, Berzofsky JA (1987) Construction of a synthetic immunogen: use of new T-helper epitope on malaria circumsporozoite protein. Science 235: 1059–1062.PubMedCrossRefGoogle Scholar
  39. Gregg I (1983) Provocation of airflow limitation by viral infection: implication for treatment. Eur J Resp Dis (suppl) 128: 369–379.Google Scholar
  40. Guillet JG, Lai MZ, Briner TJ, Buus S, Sette A, Grey HM, Smith JA, Gefter ML (1987) Immunological self, nonself discrimination. Science 235: 865–870.PubMedCrossRefGoogle Scholar
  41. Guyon-Gruaz A, Delmas A, Pedoussaut S, Halimi H, Milhaud G, Raulais D, Rivaille P (1986) Oral immunization with a synthetic peptide of cholera toxin B subunit. Eur J Biochem 159: 525–528.PubMedCrossRefGoogle Scholar
  42. Gwaltney JM, Jr (1982) Rhinoviruses. In Evans AS (ed.), Viral Infections in Humans: Epidemiology and Control. New York: Plenum Publishing Corporation, pp. 491–514.CrossRefGoogle Scholar
  43. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Bagar S, Felix AM, Heimer EP, Gillessen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM (1987) Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257–259.PubMedCrossRefGoogle Scholar
  44. Herzenberg LA, Tokuhisha T, Herzenberg LA (1980) Carrier priming leads to hapten-specific suppression. Nature 285: 664–667.PubMedCrossRefGoogle Scholar
  45. Hirayama A, Takagaki Y, Karush (1985) Interaction of monoclonal anti-bodies with lysozyme. J Immunol 134: 3241–3247.Google Scholar
  46. Ho DD, Kaplan JC, Rackaukas IE, Gurney M (1988) Second conserved domain of gp 120 is important for HIV infectivity and antibody neutralization. Science 239: 1021–1023.PubMedCrossRefGoogle Scholar
  47. Hogle JM, Chow M, Filman DJ (1985) Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229: 1358–1365.PubMedCrossRefGoogle Scholar
  48. Hopp TP (1984) Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier. Mol Immunol 21: 13–16.PubMedCrossRefGoogle Scholar
  49. Hughes PJ. North C, Jellis CH, Minor PD, Stanway G (1988) The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. J Gen Virol 69:49–58.Google Scholar
  50. Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M (1986) A synthetic peptide vaccine involving the product of the pre- S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 83: 9174–9178.PubMedCrossRefGoogle Scholar
  51. Jacob CO, Pines M, Arnon R (1984) Neutralization of heat-labile toxin of E. coli by antibodies to synthetic peptides derived from the B subunit of cholera toxin. EMBO J 3: 2889–2893.PubMedGoogle Scholar
  52. Jennings LC, Dick EC (1987) Transmission and control of rhinovirus colds. Eur J Epidemiol 3: 327–335.PubMedCrossRefGoogle Scholar
  53. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E (1981) Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature 291: 547–553.PubMedCrossRefGoogle Scholar
  54. Klipstein FA, Engert RF, Houghton RA (1986) Immunization of volunteers with a synthetic peptide vaccine for enterotoxigenic Escherichia coli. Lancet 1: 471–472.PubMedCrossRefGoogle Scholar
  55. Knopf HLS, Perkins JC, Bertran DM, Kapikian AZ, Chanock RM (1970) Analysis of the neutralizing activity in nasal wash and serum following intranasal vaccination with inactivated type 13 rhinovirus. J Immunol 104: 566–573.PubMedGoogle Scholar
  56. Krilov L, Pierik L, Keller E, Mahan K, Watson D, Hirsch M, Hamparian V, McIntosh K (1986) The association of rhinoviruses with lower respiratory tract disease in hospitalized patients. J Med Virol 19: 345–352.PubMedCrossRefGoogle Scholar
  57. Landsteiner K (1946) The specificity of immunological reactions. Harvard University Press.Google Scholar
  58. Leclerc C, Przewlocki G, Schutz MP, Chedid L (1987) A synthetic vaccine constructed by copolymerization of B and T cell determinants. Eur J Immunol 17: 269–273.PubMedCrossRefGoogle Scholar
  59. Lerner RA (1984) Antibodies of predetermined specificity in biology and medicine. Adv. Immunol 36: 1–44.PubMedCrossRefGoogle Scholar
  60. Lonberg-Holm K, Korant BD (1972) Early interaction of rhinoviruses with host cells. J Virol 9: 29–40.PubMedGoogle Scholar
  61. Luo M, Vriend G, Kamer G, Minor I, Arnold E, Rossmann MG, Boege U, Scsaba G, Duke GM, Palmenberg AC (1987) The atomic structure of Mengo Virus at 3.0 A resolution. Science 235: 182–191.PubMedCrossRefGoogle Scholar
  62. McCray JW, Werner G (1987) Different rhinovirus serotypes neutralized by antipeptide antibodies. Nature 329: 736–738.PubMedCrossRefGoogle Scholar
  63. Medappa KC, McLean C, Rueckert RR (1971) The structure of human rhinovirus 1A. Virology 44: 259–270.PubMedCrossRefGoogle Scholar
  64. Milich DR, McLachlan A, Thornton GB, Hughes JL (1987) Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site. Nature 329: 547–549.PubMedCrossRefGoogle Scholar
  65. Milstein C (1986) From antibody structure to immunological diversification of immune response. Science 231: 1261–1268.PubMedCrossRefGoogle Scholar
  66. Mitchison NA (1971) The carrier effect in the secondary response to hapten-protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis. Eur J Immunol 1: 10–19.PubMedCrossRefGoogle Scholar
  67. Mogabgab WJ, Holmes BJ, Pollack B (1975) Antigenic relationships of com-mon rhinovirus types from disabling upper respiratory illnesses. Dev Biol Stand 28: 400–411.PubMedGoogle Scholar
  68. Palmberg AC, Kirby EM, Janda MR, Drake NL, Duke GM, Potrak KF, Collett MS (1984) The nucleotide and deduced amino acid sequences of the encephalomyocarditis viral polyprotein coding region. Nucl Acids Res 12: 2969–2985.CrossRefGoogle Scholar
  69. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G, Trujillo G (1988) A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332: 158–161.PubMedCrossRefGoogle Scholar
  70. Phillpotts RJ, Tyrell DAJ (1985) Rhinovirus colds. Br Med Bul 41: 386390.Google Scholar
  71. Pierce SK, Margoliash E (1988) Antigen Processing: an interim report. Trends Biochem Sci 13: 27–29.PubMedCrossRefGoogle Scholar
  72. Przewlocki G, Audibert F, Jolivet M, Chedied L, Kent SBH, Neurath AR (1986) Production of antibodies recognizing a hepatitis B virus ( HBV) surface antigen by dministration or murabutide associated to a synthetic pre-S HBV peptide conjugated to a toxoid career. Biochem Biophys Res Commu 140: 557–564.Google Scholar
  73. Racaniello VR, Baltimore D (1981) Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci USA 78: 4887–4891.PubMedCrossRefGoogle Scholar
  74. Rossmann MG, Arnold E. Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B, Vreind G (1985) Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317: 145–153.PubMedCrossRefGoogle Scholar
  75. Rossmann MG, Arnold E, Griffith JP, Kamer G, Luo M, Smith TH, Vriend G, Rueckert RR, Sherry B, McKinley MA, Diana G, Otto M (1987) Common cold viruses. Trends Biochem Sci 12: 313–318.CrossRefGoogle Scholar
  76. Rothbard J (1987) Synthetic peptides as vaccines. Nature 330: 106–107.PubMedCrossRefGoogle Scholar
  77. Rothbard JB, Schoolnik GK (1985) The primary sequence and antigenic structure of gonococcal pilin: Approaches towards a gonococcal vaccine. Adv Exp Med Biol. 185: 247–273.Google Scholar
  78. Rueckert RR, Sherry B, Mosser A, Colonno R, Rossmann M (1986) Location of Four Neutralization Antigens on the Three-Dimensional Surface of a Common-Cold Picornavirus, Human Rhinovirus 14. In Crowell RL, Lonberg-Holm K (ed.), Virus Attachment and Entry into Cells. Washington D.C.: American Society for Microbiology, pp. 21–27.Google Scholar
  79. Sarinn PS, Sun DK, Thornton AH, Naylor pH, Goldstein AL (1986) Neutralization of HTLV-III/LAV replication by antiserum to thymosin al. Science 232: 1135–1137.CrossRefGoogle Scholar
  80. Schutze MP, Leclerc C, Jolivet M, Audibert F, Chedid L (1985) Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 135: 2319–2322.PubMedGoogle Scholar
  81. Shapira M, Arnon R (1986) In Kandell AP, Patriarca PA (eds.),. Options for the control of influenza. Lissabon, pp 391–406.Google Scholar
  82. Skern T, Sommergruber W, Blass D, Grundler P, Fraundorferr F, Pieler C, Fogy I, Kuechler E (1985) Human rhinovirus 2: complete nucleotide sequence and proteolytic processing signals in the capsid region. Nucl Acids Res 13: 2111–2126.PubMedCrossRefGoogle Scholar
  83. Stanway G, Hughes PJ, Mountford RC, Reeve P, Minor PD, Schild GC, Almond JW (1984a) Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12alb. Proc Natl Acad Sci USA 81: 1539–1543.PubMedCrossRefGoogle Scholar
  84. Stanway G, Hughes PJ, Mountford RC, Minor PD, Almond JW (1984b) The complete nucleotide sequence of a common cold virus human rhinovirus 14. Nucl Acids Res 12: 7859–7875.PubMedCrossRefGoogle Scholar
  85. Stevens VC, (1986) Current status of antifertility vaccines using gonadotropin immunogens. Immunol Today 7: 369–374CrossRefGoogle Scholar
  86. Steward MW, Howard CR (1987) Synthetic peptides: A next generation of vaccines? Immunol Today 8: 51–58.CrossRefGoogle Scholar
  87. Sutcliffe IG, Shinnick TM, Green N, Lerner RA (1983) Antibodies that react with predetermined sites on proteins. Science 219: 660–666.PubMedCrossRefGoogle Scholar
  88. Walter G (1986) Production and use of antibodies against synthetic peptides. J Immunol Methods 88: 149–161.PubMedCrossRefGoogle Scholar
  89. Watari E, Dietzschold B, Szokan G, Heber-Katz E (1987) A synthetic pep-tide induces long-term protection from lethal infection with herpes-simplex virus 2. J Exp Med 165: 459–470.PubMedCrossRefGoogle Scholar
  90. Wilson IA, Niman HL, Houghton RA, Cherenson AR, Connolly ML, Lerner RA (1984) The structure of an antigenic determinant in a protein. Cell 37: 767–778.PubMedCrossRefGoogle Scholar
  91. Wong GG, Witek JS, Temple PA, Wilkens KM, Leary AC, Luxenberg DP, Jones SS, Brown EL, Kay RM, Orr EC, Shoemaker C, Golde DW, Kaufman RJ, Hewick RM, Wang EA, Clark SC (1985) Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228: 810–814.PubMedCrossRefGoogle Scholar
  92. Yin FH, Lomax NB (1983) Host range mutants of human rhinoviruses in which non-structural proteins are altered. J Virol 48: 410–418.PubMedGoogle Scholar
  93. Zanetti M, Sercarz E, Salk J (1987) The immunology of new generation vaccines. Immunol Today 8: 18–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • Gudrun Werner
    • 1
  • Joseph W. McCray
    • 1
  1. 1.Sandoz-Forschungsinstitut GmbHViennaAustria

Personalised recommendations